Physician profile
Brian A Levitt
NPI 1285636977
$1,264.66
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,189 · 2020: $48.40 · 2021: $26.82.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,058.13 | 2019 | |
| Abbvie INC. | $45.40 | 2019-2020 | |
| Daiichi Sankyo INC. | $44.65 | 2019 | |
| Therapeuticsmd, INC. | $38.08 | 2019 | |
| Minerva Surgical, INC | $26.82 | 2021 | |
| Astellas Pharma US INC | $23.79 | 2020 | |
| Vertical Pharmaceuticals, LLC | $16.18 | 2019 | |
| Lupin INC. | $11.61 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Levitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.